+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07726433

Evaluation of Foslorapitant and Palonosetron Injection to Prevent Nausea and Vomiting in Patients Receiving Trastuzumab Rezetecan Chemotherapy

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-07-24

56

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 2 clinical trial to evaluate foslorapitant combined with palonosetron hydrochloride injection for preventing nausea and vomiting caused by treatment with trastuzumab rezetecan in patients undergoing chemotherapy. This single-arm, multicenter study involves adults aged 18 years and older who are scheduled to receive trastuzumab rezetecan. The study aims to explore the safety and effectiveness of this antiemetic regimen in reducing chemotherapy-induced nausea and vomiting CINV. Participants will receive a prophylactic antiemetic regimen consisting of foslorapitant 218 mg and palonosetron hydrochloride 0.25 mg administered intravenously one hour before chemotherapy infusion. The treatment occurs during two chemotherapy cycles, each lasting 21 days. Researchers will monitor daily vomiting frequency, nausea severity, and medication adherence throughout these cycles. During the study, participants will be closely monitored through daily logs of nausea and vomiting symptoms, use of rescue medications, and any adverse events. The primary outcome is the overall complete response rate within 120 hours after trastuzumab rezetecan infusion in the first two treatment cycles. Secondary outcomes include response rates during acute, delayed, and very delayed phases, as well as safety assessments up to 30 days after the last study drug administration. The total study duration extends through the treatment and follow-up phases ending in June 2028.

CONDITIONS

Brief Title

Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV

Research Team

Z

Zhansheng Jiang Tianjin Cancer Hospital Airport Hospital

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here